Mark Flather | Vice President of Investor Relations |
Shawn Singh | Chief Executive Officer |
Jerrold Dotson | Vice President, Chief Financial Officer and Secretary |
Mark Smith | Chief Medical Officer |
Andrew Tsai | Jefferies LLC |
Lachlan Hanbury-Brown | William Blair & Company, LLC |
Luke Herrmann | Robert W. Baird & Co. |
Michael Okunewitch | Maxim Group LLC |
Greetings, welcome to the VistaGen Therapeutics' 2022 Fiscal Year-End Results Conference Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator instructions] Please note that this conference is being recorded. I will now turn the conference over to your host, Mark Flather, Vice President of Investor Relations for VistaGen.